What off‑label medications are recommended for an adult with fibromyalgia?

Off-Label Medications for Fibromyalgia

For adults with fibromyalgia, the most strongly recommended off-label medications are gabapentin and amitriptyline, with gabapentin being particularly useful when pregabalin (FDA-approved) is not accessible or tolerated, and amitriptyline serving as a cost-effective first-line option despite insufficient evidence in recent guidelines.

Primary Off-Label Pharmacological Options

Gabapentin (Calcium Channel α2-δ Ligand)

• Mechanism and efficacy: Gabapentin binds to voltage-gated calcium channels and inhibits neurotransmitter release, showing efficacy in multiple neuropathic pain conditions 1
• Dosing considerations: Requires careful titration due to nonlinear pharmacokinetics from saturable absorption; start low and titrate gradually 2
• Common adverse effects: Dose-dependent dizziness and sedation (minimize by slow titration); requires dosage reduction in renal insufficiency 2
• Evidence base: While pregabalin has stronger evidence for fibromyalgia specifically, gabapentin shares the same mechanism and has demonstrated efficacy in chronic pain conditions 3

Amitriptyline (Tricyclic Antidepressant)

• Current guideline status: The 2022 VA/DoD guidelines state there is insufficient evidence to recommend for or against amitriptyline specifically for fibromyalgia 4
• Historical use: Older 2008 EULAR guidelines gave amitriptyline a Grade A recommendation for reducing pain and improving function 5
• Practical considerations: Often used in clinical practice due to low cost and long track record; effective for both pain and sleep disturbances 3, 6
• Important safety warnings:
  • Prescribe with caution in patients with ischemic cardiac disease or ventricular conduction abnormalities
  • Limit dosages to <100 mg/day when possible
  • Obtain screening electrocardiogram for patients >40 years old 2
  • Potentially inappropriate for adults ≥65 years due to anticholinergic effects 1
• Trial duration: Allow 6-8 weeks, including 2 weeks at highest tolerated dose, for adequate trial 2

Venlafaxine (SNRI - Off-Label Alternative to Duloxetine)

• When to consider: If duloxetine (FDA-approved SNRI) is not tolerated or accessible 4
• Dosing: Requires 2-4 weeks to titrate to efficacious dosage (150-225 mg/day); available in short- and long-acting preparations 2
• Safety concerns:
  • Cardiac conduction abnormalities reported in small numbers
  • Blood pressure increases can occur
  • Must be tapered when discontinuing due to withdrawal syndrome 2

Medications to AVOID

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)

• Strong recommendation AGAINST: The 2022 VA/DoD guidelines explicitly suggest against offering NSAIDs for chronic pain related to fibromyalgia 4
• Rationale: Limited efficacy for fibromyalgia pain; significant gastrointestinal and cardiovascular risks 1

Opioids

• Strong recommendation AGAINST: The 2022 VA/DoD guidelines recommend against long-term opioid use for chronic pain in fibromyalgia patients 4
• Evidence: No placebo-controlled trials demonstrate long-term effectiveness; associated with increased risks of addiction, overdose, falls, and fractures 1
• Exception: Tramadol (weak opioid) received Grade A recommendation in older 2008 EULAR guidelines 5, but current practice emphasizes caution

SSRIs (Selective Serotonin Reuptake Inhibitors)

• Insufficient evidence: The 2022 VA/DoD guidelines state insufficient evidence to recommend for or against SSRIs for fibromyalgia 4
• Less effective than SNRIs: SNRIs (duloxetine, milnacipran) have stronger evidence than SSRIs 3

Clinical Algorithm for Off-Label Selection

Step 1: Start with FDA-approved options when possible

• Pregabalin, duloxetine, or milnacipran should be first-line if accessible 4, 1, 7

Step 2: If FDA-approved drugs fail or are contraindicated, consider:

• Gabapentin if pregabalin not tolerated or too expensive (similar mechanism, requires more careful titration)
• Amitriptyline if patient has prominent sleep disturbance AND is <65 years old AND has no cardiac disease
• Venlafaxine if duloxetine not tolerated AND patient has no cardiac disease

Step 3: Avoid polypharmacy pitfalls

• One-third of patients on gabapentinoids also receive opioids or tramadol 8 - this combination increases harm risk
• Gabapentinoid use more prevalent with depression (OR=4.51) and anxiety (OR=3.69) 8
• Consider whether psychiatric comorbidities are driving prescribing patterns rather than fibromyalgia itself

Step 4: Set realistic expectations

• No single drug controls all fibromyalgia symptoms 9, 10
• Effect sizes for most treatments are modest 11
• Target average pain reduction to ≤3/10 as success metric 2

Key Caveats and Common Pitfalls

Cardiovascular Screening

• Critical for tricyclics: ECG mandatory for patients >40 years before starting amitriptyline 2
• Venlafaxine monitoring: Check blood pressure; avoid in cardiac disease 2

Renal Function

• Both gabapentin and pregabalin require dose adjustment based on creatinine clearance 2
• Failure to adjust for renal insufficiency increases adverse effects

Misuse Potential

• Gabapentinoids have emerging concerns for misuse and dependence 8
• Particularly problematic when combined with opioids or in patients with substance use history

Age Considerations

• Amitriptyline potentially inappropriate for ≥65 years due to anticholinergic burden 1
• Older adults may tolerate SNRIs or gabapentinoids better

Trial Duration

• Allow adequate trial periods: 6-8 weeks for tricyclics 2, 2-4 weeks for adequate SNRI titration 2
• Premature discontinuation leads to false treatment failures

Integration with Non-Pharmacological Approaches

The 2017 EULAR guidelines provide the only "strong for" recommendation: exercise 11. The 2022 VA/DoD guidelines suggest:

• Cognitive-behavioral therapy 4
• Mindfulness-based therapies 4
• Physical exercise 4
• Yoga or tai chi 4

Off-label medications should complement, not replace, these evidence-based non-pharmacological interventions 11, 6.